Friday, March 8, 2013
ADMA Biologics Inc., of Hackensack, N.J., enrolled its first patient in a Phase III trial of RI-002, an immune globulin, for primary immune deficiency diseases (PIDD). The trial will enroll 60 to 70 patients for a 12-month treatment period followed by up to 90 days safety monitoring and follow-up. Its goal will be to evaluate safety and efficacy of the drug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.